Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 9, 2018

Primary Completion Date

January 20, 2023

Study Completion Date

January 20, 2023

Conditions
Cardiomyopathy, Hypertrophic
Interventions
DEVICE

Active pacing

Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.

DEVICE

Back-up pacing

Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.

Trial Locations (1)

EC1A 7BE

Barts Heart Centre, London

All Listed Sponsors
lead

Barts & The London NHS Trust

OTHER

NCT03450252 - Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter